This image is a representation. Your design will be featured in the final product.

OROSOL : treatment of oral mucositis

OROSOL is an innovative oral spray designed to treat oral mucositis induced by radiotherapy or chemotherapy. With its protective barrier effect, osmotic and cleaning effect, as well as cellular repair and growth effect, OROSOL provides a significant reduction in pain, burns, infections, and mucositis in as little as 20 minutes. Clinical results show continued improvement with regular use, offering patients long-lasting relief and improved quality of life.

Clinical trial

Randomized, double-blind, placebo-controlled trial


This product is intended for adult use


Treatment of oral mucositis induced by radio or chemotherapy


OROSOL is a revolutionary product designed to provide relief and treatment for oral mucositis induced by radiotherapy or chemotherapy. This throat spray, presented in a 20ml bottle, targets pro-inflammatory proteins, contaminants, and impurities, offering a threefold action for optimal results.

Mode of action

Protective Barrier Effect:

MucositisOROSOL creates a protective barrier in the oral cavity, shielding the mucous membranes from further damage and allowing the healing process to begin.


Osmotic and Cleaning Effect:

The product works to cleanse the oral cavity, removing impurities and contaminants that can exacerbate inflammation and delay healing.


Cellular Repair and Growth Effect:

MucositisOROSOL promotes the repair and growth of cells in the oral cavity, accelerating the healing process and reducing the duration of symptoms.


Clinical Trial

In a randomized, double-blind, placebo-controlled clinical trial conducted over six weeks, MucositisOROSOL demonstrated significant efficacy. Patients experienced a 23% reduction in mucus in just two days, and a 35% reduction in mucositis in three days. By the end of one month, mucositis was reduced by 69%.

The product also showed remarkable results in pain management, with a 34% reduction in pain in just 20 minutes, and a 72% reduction in pain by the end of one month.

In addition to its effects on mucositis and pain, OROSOL also demonstrated a significant reduction in burns and infections associated with oral mucositis. By the end of one month, burns were reduced by 74%, and infections were reduced by 75%.


These results highlight the potential of OROSOL as a powerful tool in the management of oral mucositis induced by radiotherapy or chemotherapy. Its multi-faceted approach not only alleviates symptoms but also promotes healing, offering patients a more comfortable and swift recovery.

See full publication (PDF)


Product Details

  • Indication: Filmogen liquid bandage for the treatment of oral mucositis induced by radiotherapy or chemotherapy.
  • Composition: Filmogenic glycerol, honey, water, association of Vaccinium macrocarpon and Vaccinium myrtillus.
  • Presentation: Throat spray 20ml.
  • Class: Current certification: MDD Class IIa | Certification in progress: MDR Class IIa.
  • Direction: Apply 2 sprays in the throat, 2-3 times a day.
  • Precautions: For topical use only (nasal cavity). Keep out of reach and sight of children.
  • Age: 18+.
  • Storage conditions: Below 25°C.
  • Legal manufacturer: VITROBIO (France).
  • Product code: OS.